Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects

Retina

Volumn 32, Issue 6, 2012, Pages 1197-1203

  Paine, Suman K ^a   Sen, Aditi ^a   Choudhuri, Subhadip ^a   Mondal, Lakshmi K ^b   Chowdhury, Imran H ^a   Basu, Analabha ^c   Mukherjee, Ankur ^c   Bhattacharya, Basudev ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b Regional Institute of Ophthalmology   (India)

^c NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

Author keywords

M2 macrophage; neovascularization; proliferative diabetic retinopathy; SNP

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATHOGENESIS; POLYMERASE CHAIN REACTION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861801828     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822f55f3     Document Type: Article

References (37)

1. Abu El-Asar AM, Al-Mezaine HS, Ola MS. Pathophysiology and management of diabetic retinopathy. Exp Rev Opthalmol 2009;4:627-647.
2. Khan ZA, Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabetes Res 2003;4:287-301.
3. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemio-logic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.
4. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 1998;39:1647-1657.
5. Zhang W, Ito Y, Berlin E, et al. Role of hypoxia during normal retinal vessel development and in experimental retinop-athy of prematurity. Invest Ophthalmol Vis Sci 2003;44: 3119-3123.
6. Yoshihiro W, Yoshihiko U, Yoko O, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 2010;30:339-344.
7. Sulochana KN, Ramakrishnan S, Rajesh M, et al. Diabetic retinopathy: molecular mechanisms, present regime of treatment and future perspectives. Curr Sci 2001;80:133-142.
8. Hideharu F, Hidetoshi Y, Erika S, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001;21:469-477.
9. Mantovani A, Sozzani S, Locati MP, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclearphagocytes. Trends Immunol 2002;23:549-555.
10. Kelly J, Ali Khan A, Yin J, et al. Senescence regulates mac-rophage activation and angiogenic fate at sites of tissue injury in mice. J Clin Invest 2007;117:3421-3426.
11. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-346.
12. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-686.
13. Uthra S, Raman R, Mukesh BN, et al. Genetics of diabetic retinopathy. Int J Hum Genet 2008;8:155-159.
14. Zornea K, Mysliwska J, Mysliwiec M, et al. Serum TNF-alpha level predicts non proliferative diabetic retinopathy in children. Mediators Inflamm 2007:92916.
15. Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl 2003;9:170-181.
16. Bailey JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-329.
17. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 2006.
18. Fauc AS, Brawnwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Lascalzo J. Diabetes mellitus, Power AC; Harrison's principle of internal medicine 2008;2:2275-2310.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
20. Knight JC, McGuire W, Kortok MM, Kwiatkowski D. Accuracy of genotyping of single-nucleotide polymorphisms by PCR-ELISA allele-specific oligonucleotide hybridization typing and by amplification refractory mutation system. Clin Chem 1999;45:1860-1863.
21. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2:25-31.
22. Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor-a. Eur J Biochem 1991;202: 3-14.
23. Vinores SA, Xiao WH, Shen J, Campochiaro PA. TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neo-vascularization nor VEGF-induced leakage. J Neuroimmunol 2007;182:73-79.
24. Balasubramanyam M, Rema M, Premanand C. Biochemical and molecular mechanisms of diabeticretinopathy. Curr Diabetes Rev 2005;83:73-81.
25. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113: 401-406.
26. Tekeli O, Turacli ME, Egin Y, et al. Tumor necrosis factor alpha-308 gene polymorphism and pseudoexfoliation glaucoma. Mol Vis 2008;14:1815-1818.
27. Sen A, Paine SK, Chowdhury IH, et al. Association of inter-feron gamma, interleukin-10 and tumor necrosis factor alpha gene polymorphisms with occurrence and severity of Eales' disease. Invest Ophthalmol Vis Sci 2011;52:171-178.
28. Rowley M, Ness BV. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene 2002;21: 8769-8775.
29. Bamforth SD, Lightman S, Greenwood J. The effect of TNF-a and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropathologica 2007;91:624-632.
30. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102: 1369-1376.
31. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005;10: 191-198.
32. Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med 2006;3:e310.
33. Dace DS, Khan AA, Kelly J, Apte RS. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One 2008;3:e3381.
34. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascu-larization in ischemic retinopathy. J Clin Invest 2001;107: 717-725.
35. Fischer S, Clauss M, Wiesnet M, et al. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO. Am J Physiol Cell Physiol 1999;276:C812-C820.
36. Wilson JN, Rockett K, Jallow M, et al. Analysis of IL10 hap-lotypic association with severe malaria. Genes Immun 2005;6: 462-466.
37. Alder VA, Su EN, Yu DY, et al. Diabetic retinopathy: early functional changes. Clin Exp Pharmol Physiol 1997;24: 785-788.